Reading Contemporary Russian Women s Comics – Shenandoah Volume 72 Issue 2 shenandoahliterary.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from shenandoahliterary.org Daily Mail and Mail on Sunday newspapers.
Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market
- Listing to fund the clinical development of sevuparin for sepsis/septic shock
- No pharmaceutical products are currently available that are specifically meant to treat patients with sepsis/septic shock
News provided by
Share this article
STOCKHOLM, March 15, 2021 /PRNewswire/
Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, announces that it has appointed Sedermera Fondkommission as financial adviser to support its planned listing on Nasdaq First North Growth Market. The engagement of Sedermera Fondkommission follows the appointment of Claes Lindblad at Modus Therapeutics as its new Chief Financial Officer.
Modus Therapeutics
Share this article
STOCKHOLM, March 12, 2021 /PRNewswire/
Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, announces that it has appointed Claes Lindblad as its new Chief Financial Officer. He joins the Company as it looks for funding to support the development of sevuparin, into a new important potential treatment for sepsis/septic shock, and other severe inflammatory complications that millions of patients suffer from because of serious medical conditions such as major trauma and surgery, autoimmunity, and viral infection.
In many patients, these severe conditions result in severe uncontrolled systemic inflammation (also known as systemic inflammatory response syndrome, SIRS), which can then progress into shock and multi-organ failure. One example being septic shock, which is a leading cause of death in intensive care units worldwide, with mortality rates typically exceeding 30%. There i